Iceland· IS-EU/1/15/1056/001
Praxbind
A idarucizumab product containing idarucizumabum inn, registered in Iceland by Boehringer Ingelheim International GmbH*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Idarucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC V03AB37 (idarucizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Idarucizumab · ATC V03AB37
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Idarucizumabum INN
- Manufacturer
- Boehringer Ingelheim International GmbH*
- Country
- Iceland (IS)
- ATC code
- V03AB37
- ATC class
- Idarucizumab
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean45041350 ml x2 hglISK 417401
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPraxbind 2.5 g/50 mlBoehringer Ingelheim International
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- IrelandPraxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim International GmbH
- NorwayPraxbindBoehringer Ingelheim International GmbH
- PolandPraxbindBoehringer Ingelheim International GmbH
- SwedenPraxbind 50 mg/ml Injektions-/infusionsvätska, lösningBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4150f14c-cf85-43ff-9f98-2448a6e76c5e GET /v1/drugs/4150f14c-cf85-43ff-9f98-2448a6e76c5e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf/innrennslislyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "V03AB37",
"marketed": true,
"strength": "2,5 g/50 ml",
"ma_number": "EU/1/15/1056/001",
"substance": "Idarucizumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "42328"
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.